Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2140023 Dose Ranging Study in Schizophrenia
NCT00520923Phase 2Completed
- Sponsor
- Denovo Biopharma
- Start
- Sep 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of pomaglumetad methionil in schizophrenia, sponsored by Denovo Biopharma. Started Sep 2007; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00520923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520923.